Cantor Fitzgerald Has Negative View of ZVRA FY2024 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Research analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for Zevra Therapeutics in a research report issued on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will earn ($1.97) per share for the year, down from their prior forecast of ($1.61). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.92) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same period in the prior year, the company earned ($0.40) EPS.

A number of other equities research analysts also recently issued reports on ZVRA. William Blair raised Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Canaccord Genuity Group reduced their target price on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. JMP Securities began coverage on Zevra Therapeutics in a report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 target price on the stock. Guggenheim began coverage on Zevra Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $20.00 target price on the stock. Finally, Maxim Group raised their target price on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zevra Therapeutics presently has a consensus rating of “Buy” and an average price target of $21.00.

Zevra Therapeutics Trading Down 0.2 %

Shares of NASDAQ:ZVRA opened at $8.60 on Monday. The company has a market capitalization of $452.53 million, a P/E ratio of -4.28 and a beta of 1.93. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.21. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.00. The business’s 50 day simple moving average is $8.03 and its 200 day simple moving average is $6.51.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. International Assets Investment Management LLC lifted its stake in shares of Zevra Therapeutics by 594.0% in the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock valued at $48,000 after acquiring an additional 5,940 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in shares of Zevra Therapeutics in the 1st quarter valued at $64,000. The Manufacturers Life Insurance Company lifted its stake in shares of Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after acquiring an additional 2,452 shares during the last quarter. Hunter Associates Investment Management LLC bought a new position in shares of Zevra Therapeutics in the 3rd quarter valued at $92,000. Finally, XTX Topco Ltd bought a new position in shares of Zevra Therapeutics in the 3rd quarter valued at $94,000. 35.03% of the stock is currently owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.